The variety of sales figures and pipeline updates for antiviral drugs and vaccines for SARS-CoV-2 coming out in various drug makers’ second-quarter earnings illustrate just how much the COVID-19 treatment landscape has changed over the past year, with some drugs once viewed as promising now pulled from shelves while next-generation products that could treat newer strains inch toward the market.
To be sure, some of the products that have been around for a while are still going strong. Pfizer Inc./BioNTech SE’s vaccine Comirnaty raked in sales of more than $8bn during the quarter, while sales of Moderna, Inc.’s Spikevax came in at more than half of that. Sales of the two marketed oral drugs, Pfizer’s Paxlovid (nirmatrelvir and ritonavir) and Merck & Co., Inc./Ridgeback Biotherapeutics LP’s Lagevrio (molnupiravir), have also stayed well within blockbuster range. (Also see "Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers" - Scrip, 28 July, 2022.). Gilead Sciences, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
